Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | JAK2 | O60674 | 1/20 | 0.55 |
| ▸ | JAK1 | P23458 | 1/20 | 0.55 |
| ▸ | TYK2 | P29597 | 1/20 | 0.55 |
| ▸ | CES2 | O00748 | 2/20 | 0.52 |
| ▸ | MRGPRX4 | Q96LA9 | 1/20 | 0.47 |
| ▸ | TRPV1 | Q8NER1 | 1/20 | 0.47 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.44 |
| ▸ | HPGD | P15428 | 2/20 | 0.44 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.44 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.44 |
| ▸ | RORC | P51449 | 1/20 | 0.44 |
| ▸ | RORB | Q92753 | 1/20 | 0.44 |
| ▸ | TSHR | P16473 | 2/20 | 0.44 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.44 |
| ▸ | MEN1 | O00255 | 1/20 | 0.44 |
| ▸ | ATM | Q13315 | 1/20 | 0.44 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.44 |
| ▸ | LMNA | P02545 | 1/20 | 0.43 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.43 |
| ▸ | PDE2A | O00408 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10658142 | 0.86 | JAK2 (0.56) | JAK2JAK1TYK2CES2MRGPRX4 | |
| SCHEMBL78221 | 0.85 | MRGPRX4 (0.61) | JAK2JAK1TYK2CES2MRGPRX4 | |
| SCHEMBL1455625 | 0.85 | CES2 (0.52) | JAK2JAK1TYK2CES2MRGPRX4 | |
| SCHEMBL1199588 | 0.83 | JAK2 (0.57) | JAK2JAK1TYK2CES2MRGPRX4 | |
| SCHEMBL30740081 | 0.83 | JAK2 (0.57) | JAK2JAK1TYK2CES2MRGPRX4 | |
| SCHEMBL30094862 | 0.83 | JAK2 (0.54) | JAK2JAK1TYK2CES2MRGPRX4 | |
| SCHEMBL15697514 | 0.83 | JAK2 (0.54) | JAK2JAK1TYK2CES2MRGPRX4 | |
| Hydrochloric Acid SCHEMBL18861026 | 0.83 | MRGPRX4 (0.59) | JAK2JAK1TYK2CES2MRGPRX4 | |
| SCHEMBL629096 | 0.83 | CASP1 (0.55) | JAK2JAK1TYK2CES2MRGPRX4 | |
| SCHEMBL24073216 | 0.82 | ALDH1A1 (0.62) | JAK2JAK1TYK2CES2MRGPRX4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 131 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-119431900-A | Polymer-ceramic composite dielectric material, preparation method and application thereof in capacitor | 武汉攀新科技有限公司 | 2025-02-14 | — | — | CN | claimed |
| EP-3274339-B1 | PROCESS FOR THE PREPARATION OF 2- (HOMO)PIPERAZINE 1,3-BENZOTHIAZINE-4-ONE HYDROCHLORIDES | ECOLE POLYTECHNIQUE FED LAUSANNE EPFL (CH) | 2021-10-13 | — | — | EP | claimed |
| CN-107567439-B | 2-homopiperazin-1-yl-4H-1, 3-benzothiazin-4-one derivatives and process for preparing 2- (homo) piperazine-1, 3-benzothiazin-4-one hydrochloride | 洛桑联邦理工学院 | 2021-04-16 | — | — | CN | claimed |
| US-10160754-B2 | 2-homopiperazine-1-yl-4H-1,3-benzothiazine-4-one derivatives and process for the preparation of 2-(homo)piperazine 1,3-benzothiazine-4-one hydrochlorides | ECOLE POLYTECHNIQUE FEDERALE DE LAUSANNE (EPFL) (CH) | 2018-12-25 | — | — | US | claimed |
| US-20180051016-A1 | 2-HOMOPIPERAZINE-1-YL-4H-1,3-BENZOTHIAZINE-4-ONE DERIVATIVES AND PROCESS FOR THE PREPARATION OF 2- (HOMO)PIPERAZINE 1,3-BENZOTHIAZINE-4-ONE HYDROCHLORIDES | ECOLE POLYTECHNIQUE FEDERALE DE LAUSANNE (EPFL) (CH) | 2018-02-22 | — | — | US | claimed |
| EP-3072889-A1 | 2-Homopiperazine-1-yl-4H-1,3-benzothiazine-4-one derivatives and process for the preparation of 2-(homo)piperazine 1,3-benzothiazine-4-one hydrochlorides | ECOLE POLYTECHNIQUE FEDERALE DE LAUSANNE (EPFL) (CH) | 2016-09-28 | — | — | EP | claimed |
| EP-3340988-B1 | ION CHANNEL INHIBITORY COMPOUNDS, PHARMACEUTICAL FORMULATIONS AND USES | AFASCI INC (US) | 2025-04-09 | — | — | EP | disclosed |
| CN-119431900-A | Polymer-ceramic composite dielectric material, preparation method and application thereof in capacitor | 武汉攀新科技有限公司 | 2025-02-14 | — | — | CN | disclosed |
| US-20240139214-A1 | AGENT FOR SUPPRESSING IL-31 PRODUCTION AND PHARMACEUTICAL COMPOSITION CONTAINING THE SAME | KYUSHU UNIVERSITY, NATIONAL UNIVERSITY CORPORATION (JP) | 2024-05-02 | — | — | US | disclosed |
| EP-4289422-A1 | AGENT FOR SUPPRESSING IL-31 PRODUCTION AND PHARMACEUTICAL COMPOSITION CONTAINING THE SAME | Kyushu University, National University Corporation (JP) | 2023-12-13 | — | — | EP | disclosed |
| CN-117042759-A | IL-31 production inhibitor and pharmaceutical composition containing the same | 国立大学法人九州大学 | 2023-11-10 | — | — | CN | disclosed |
| WO-2022168962-A1 | AGENT FOR SUPPRESSING IL-31 PRODUCTION AND PHARMACEUTICAL COMPOSITION CONTAINING THE SAME | 国立大学法人九州大学 | 2022-08-11 | — | — | WO | disclosed |
| CN-108289886-B | Ion channel inhibiting compounds, pharmaceutical formulations and uses | 安华赛公司 | 2022-01-28 | — | — | CN | disclosed |
| WO-2002068417-A3 | HETEROPOLYCYCLIC COMPOUNDS AND THEIR USE AS METABOTROPIC GLUTAMATE RECEPTOR ANTAGONISTS | SLASSI ABDELMALIK (CA) | 2002-11-14 | — | — | WO | disclosed |
| CN-1379775-A | Heteropolycyclic compounds and their use as metabotropic glutamate receptor antagonists | NPS PHARMA INC (US) | 2002-11-13 | — | — | CN | disclosed |
| WO-2002068417-A2 | HETEROPOLYCYCLIC COMPOUNDS AND THEIR USE AS METABOTROPIC GLUTAMATE RECEPTOR ANTAGONISTS | NPS PHARMACEUTICALS, INC. (US) | 2002-09-06 | — | — | WO | disclosed |
| EP-1210344-A1 | HETEROPOLYCYCLIC COMPOUNDS AND THEIR USE AS METABOTROPIC GLUTAMATE RECEPTOR ANTAGONISTS | NPS PHARMACEUTICALS, INC. (US) | 2002-06-05 | — | — | EP | disclosed |
| WO-2001012627-A1 | HETEROPOLYCYCLIC COMPOUNDS AND THEIR USE AS METABOTROPIC GLUTAMATE RECEPTOR ANTAGONISTS | NPS PHARMACEUTICALS, INC. (US) | 2001-02-22 | — | — | WO | disclosed |
| US-4792606-A | CATALYTIC REACTION OF AROMATIC ACYLHALIDE WITH ALKALI METAL CYANIDE | BAYER AKTIENGESELLSCHAFT (DE) | 1988-12-20 | — | — | US | disclosed |
| EP-0255664-A2 | Process for the preparation of dimeric aromatic acylcyanides | BAYER AG (DE) | 1988-02-10 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10160754-B2 | 2-homopiperazine-1-yl-4H-1,3-benzothiazine-4-one derivatives and process for the preparation of 2-(homo)piperazine 1,3-benzothiazine-4-one hydrochlorides | HBZ, HARS1, HCLS1 | JAK2 496/4885JAK1 481/4885TYK2 1954/4885 |
| US-20240139214-A1 | AGENT FOR SUPPRESSING IL-31 PRODUCTION AND PHARMACEUTICAL COMPOSITION CONTAINING THE SAME | IL36G, IL1RN, IL1B | JAK2 32/4885JAK1 27/4885TYK2 410/4885 |
| US-20180051016-A1 | 2-HOMOPIPERAZINE-1-YL-4H-1,3-BENZOTHIAZINE-4-ONE DERIVATIVES AND PROCESS FOR THE PREPARATION OF 2- (HOMO)PIPERAZINE 1,3-BENZOTHIAZINE-4-ONE HYDROCHLORIDES | HBZ, HARS1, HCLS1 | JAK2 496/4885JAK1 481/4885TYK2 1954/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.